# Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer

> **NCT01938638** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 80 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BAY1143572

## Key facts

- **NCT ID:** NCT01938638
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-26
- **Primary completion:** 2016-08-17
- **Final completion:** 2016-09-19
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01938638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01938638, "Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01938638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*